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February 2016 Abstracts S21level, with copy number gain and/or promoter hypo-
methylation occurring in 50-60% of tumors. Mutation
was not a frequent event. Importantly, the ELF3 locus
at 1q32.1 was focally ampliﬁed in 14.0% of tumors
(q value¼4.44E-05), compared to recently described
driver ampliﬁcations at MET (7.1%) and ERBB2
(8.2%). DNA-level selection of ELF3 was observed in
56% of tumors with no known driver, and was sta-
tistically enriched in KRAS mutant tumors and patients
who smoked. In vitro knock-down of ELF3 in AC cell
lines lead to signiﬁcantly reduced proliferation and
fewer colonies formed, while overexpression of ELF3
in HBECs lead to signiﬁcantly increased proliferation.
ELF3 overexpression alone was not sufﬁcient to
transform HBECs. In vivo, tumors with knock-down of
ELF3 displayed a trend towards decreased growth
over time (p¼0.08). ELF3 localization was found to be
nuclear in both cell lines and tumor specimens,
consistent with its function as a transcription factor.
Conclusions: Ampliﬁcation and hypomethylation of the
ELF3 locus is sufﬁcient to de-couple the dependence of
ELF3 overexpression on SMAD4 loss. Furthermore, ELF3
is a novel candidate oncogene on chromosome 1q, a
region that has remained “driverless” for some time.
Focal ampliﬁcation of ELF3 occurred at a higher fre-
quency than MET and ERBB2, recently described drivers
of lung AC, while additional DNA-level mechanisms of
selection occurred in over half of cases with no known
driver. Manipulation of ELF3 levels in cell models
demonstrated a clear role in the regulation of prolifer-
ation; further studies are warranted to determine the
potential of ELF3 as a pharmaceutical target.Detection of a novel RET gene fusion
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Introduction: In lung cancer, several driver Receptor
Tyrosine Kinases (RTKs) have been identiﬁed in gene
fusions, including ALK, RET, ROS1, NTRK1, NRG1 and
FGFR1/2/3. These oncogenic gene fusions have become
either direct targets or biomarkers for molecular ther-
apies for patients with lung cancer. Screening patients
for the presence of these gene fusions would be critical
for oncologists to select appropriate therapeutic
intervention or for drug developers to design noveltherapeutics and conduct clinical trials. However,
detection of fusions, especially unknown fusions, from
FFPE samples is challenging for many diagnostic tech-
niques. ArcherTM FusionPlexTM Lung Thyroid Panel is
built on Anchored Multiplex PCR (AMPTM) Chemistry,
allowing detection of both novel and known fusions.
Here we report the results from our study using the
Archer Lung-Thyroid Panel. We identiﬁed and veriﬁed
the presence of a novel fusion between Myosin Phos-
phatase Rho Interacting Protein (MPRIP) and RET
oncogene, in an FFPE sample from a non-small cell lung
cancer (NSCLC) patient.
Methods: FFPE samples from 20 NSCLC patients
were analyzed in the study. An RNA sample con-
taining an ALK and ROS1 fusion was used as the
positive control, and FFPE processed GM12878 was
used as the negative control. In addition, FFPE con-
trols containing TMP3-NTRK1 and CCDC6-RET were
also used to evaluate the performance of the panel to
detect fusions. Total nucleic acid (TNA) was extrac-
ted from the FFPE sections using the AgencourtTM
FORMAPURETM kit. For each sample, 200 ng of TNA
was used for library preparation. The barcoded
libraries from 14 samples were pooled and
sequenced on an Illumina MiSeq using a v2 ﬂow cell.
The FASTA ﬁles from the MiSeq were then analyzed
by the ArcherDX data analysis pipeline to determine
the presence of gene fusions with driver genes
including ALK, FGFR3, MET, NTRK1, NTRK3, NTRK3,
PPARG, RET, and ROS1. The detected fusions in
clinical samples were further conﬁrmed by Sanger
sequencing and FISH.
Results: The known fusions, including EM4-ALK,
SLC34A2-ROS1, TMP3-NTRK1, and CCDC6-RET were
successfully detected in the positive RNA and FFPE
control samples. For all of the clinical FFPE samples,
one 10 micron section was sufﬁcient to yield more
than the required 200 ng TNA for library preparation.
Although three of the twenty (15%) FFPE samples
failed the initial sample quality metrics, libraries were
prepared for all 20 NCSLC FFPE samples and
sequenced on MiSeq. Among the three samples that
did not pass the initial sample QC, two of them also
failed the QC metrics for fusion detection. From the
seventeen samples that did pass the initial QC, one
sample failed the fusion QC. Overall, the success rate
for the clinical samples tested with this panel was
85%. Among the 20 NSCLC samples, one sample was
found to harbor a novel, in-frame fusion between exon
19 of MPRIP and exon 12 of RET. This type of fusion
would retain an intact kinase domain (exons 12-18) of
RET, and would presumably be oncogenic. Using
the RNA portion of the TNA extracted, cDNA was
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sequenced by Sanger. The results conﬁrmed the
presence of an RNA transcript spanning exon 19 of
MPRIP and exon 12 of RET. Furthermore, FISH was
performed with the RET (10q11.2) break-apart probe,
and conﬁrmed the rearrangement involving the RET
region of chromosome 10.
Conclusions: These results show the ArcherTM Fusion-
PlexTM Lung Thyroid Panel can accurately detect gene
fusions with both known and unknown partner and
driver genes. Further investigation is needed to better
understand the clinical signiﬁcance and prevalence of
the novel MPRIP and RET fusion.
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Inﬂammation often characterizes the pulmonary tumor
microenvironment, as does overexpression of the tran-
scriptional repressors of E-cadherin (e.g., Snail and Slug).
While chronic inﬂammation is now associated with
increased lung cancer incidence, Snail and Slug are still
best known for their induction of epithelial-mesen-
chymal transition (EMT) and their contribution to the
progression of established lung cancer. Our bioinfor-
matics analysis of lung TCGA data suggests that Slug is
among the most impactful of all the transcriptional re-
pressors on patient survival. Therefore, we are now
exploring the scope of malignant phenotypes and
mechanisms induced by Slug expression in a non-small
cell lung cancer (NSCLC) model. We discovered that
NSCLC cells exposed to the prototypical inﬂammatory
mediator IL-1B respond with downregulation of epithe-
lial markers (E-cadherin and cytokeratin 18) and upre-
gulation of mesenchymal markers (N-cadherin and
vimentin), with the repression of E-cadherin by IL-1B
being Slug-dependent. NSCLC cells exposed to IL-1B also
demonstrate altered cellular morphology, diminished
capacity to form clusters in a 3-dimensional (3D)
spheroid model, and increased motility. Using chemical
inhibitors of the JNK, MEK/ERK, p38 MAPK, and NF-lB
pathways, we determined that JNK and MEK/ERK
mediate IL-1B induction of EMT in lung cancer cells.
Furthermore, siRNA-mediated knockdown of the Fra-1
component of the AP-1 transcription factor abolished the
impact of IL-1B on Slug and E-cadherin in this model,demonstrating a mechanistic link between inﬂammation
and Slug-dependent progression of established lung
cancer. Because we have identiﬁed a critical role for
Snail in lung cancer initiation, we next investigated the
contribution of Slug to early lung cancer development.
Using human bronchial epithelial cells (HBECs) engi-
neered to express Slug to model pulmonary pre-
malignancy, we observed a diverse array of potentially
malignant phenotypes, including EMT, increased pro-
duction of the pro-angiogenic chemokine CXCL8,
enhanced invasion in a 3D air-liquid interface model, and
anchorage-independent growth in vitro. Furthermore,
we determined that the Slug-driven transformation
observed in vitro was not contingent upon an altered
proliferation rate, but was more likely related to Slug-
driven disruption of stem cell signaling programs. Taken
together, our data suggest that Slug may be important
in the setting of lung carcinogenesis and that its impact
on carcinogenesis extends beyond its repression of
E-cadherin. Our data also suggest that Slug may play an
important role in the initiation and progression of early
stage NSCLC.
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Playing a central role in regulating DNA synthesis and
repair, proliferating cell nuclear antigen (PCNA) is
indispensable to cancer cell growth and survival. It,
therefore, represents a potential molecular target to
develop broad-spectrum anti-cancer agents. We discov-
ered a cancer-associated isoform of PCNA (caPCNA),
which is ubiquitously and highly expressed in a broad
range of cancer cells and tumor tissues. In contrast, this
PCNA isoform is not signiﬁcantly expressed in non-
malignant cells. The secondarily modiﬁed region dis-
tinguishing caPCNA from normal PCNA expressed in
non-malignant cells lies between L126 and Y133 within
the interconnector domain of PCNA known to be a major
binding site for many of PCNA’s interacting proteins. A
cell permeable peptide containing the L126-Y133
sequence blocks PCNA interaction, interferes with
DNA replication and homologous combination mediated
DNA repair, and induces apoptosis in cancer cells. In
contrast, this peptide causes no signiﬁcant toxicity to
